AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
May 22, 2012
29977_dirs_2012-05-22_6015e849-9af5-4920-afb6-1c6020fd00e3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-05-21
Reporting Person: GOLDBERG MURRAY A (SVP Finance and Admin CFO Trea)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-05-21 | Common Stock | M | 4562.0 | $21.92 | Acquired | 84728.0 | Direct |
| 2012-05-21 | Common Stock | M | 11682.0 | $11.64 | Acquired | 96410.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-05-21 | Incentive Stock Option (right to buy) | $11.64 | M | 11682.0 | Disposed | 2015-12-19 | Common Stock (11682.0) | Direct |
| 2012-05-21 | Incentive Stock Option (right to buy) | $21.92 | M | 4562.0 | Disposed | 2017-12-17 | Common Stock (4562.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5560.0 | Indirect |
Footnotes
F1: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
F2: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3